cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Novo Nordisk's outperforms Ozempic in III trial Novo Nordisk's next-gen drug – FDA Grants Accelerated Approval Quantity:100 Pack Type_Multi dose vials

cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Novo Nordisk's outperforms Ozempic in III trial Novo Nordisk's next-gen drug – FDA Grants Accelerated Approval Quantity:100 Pack Type_Multi dose vials

FDA Grants Accelerated Approval to Iberdomide With Daratumumab and Hyaluronidase-Fihj and Dexamethasone for Multiple Myeloma | Oncology Nursing Society

LGR1, leucine-rich alpha-2-glycoprotein 1

Type_Multi dose vials

Quantity:100 Pack

Funding This work was supported by the National Natural Science Foundation of China (82372405, 81871752), the Key Research and Development Program of Hubei Province (2022BCA052), the Key Research and Development Program of Wuhan City (2024020702030105), the Fundamental Research Funds for the Central Universities (2042023kf0199), and the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University (ZNJC202014)